INVESTIGATIONAL trastuzumab rezetecan provides robust survival benefits for patients with HER2-positive metastatic breast cancer. In the multicenter Phase 3 HORIZON-Breast01 trial, the next-generation antibody-drug conjugate demonstrated profound antitumor efficacy compared with standard pyrotinib plus capecitabine in individuals previously treated with trastuzumab and a taxane. These interim findings offer compelling evidence for establishing a potent, highly selective therapeutic standard in pretreated advanced oncologic settings.
Patients receiving trastuzumab rezetecan achieved a median progression-free survival of 30.6 months, compared to 8.3 months in the control group. This marked difference corresponds to a 78% reduction in the risk of disease progression or mortality. The confirmed objective response rate reached 81.7% in the investigational cohort versus 58.2% among patients receiving pyrotinib plus capecitabine. Sustained disease control was further reflected by a median duration of response of 27.8 months with the novel conjugate, underscoring durable tumor suppression across diverse clinical subgroups.
The biological design of trastuzumab rezetecan incorporates an anti-HER2 monoclonal antibody linked to a novel topoisomerase I inhibitor payload via an enzymatically cleavable linker. This structure delivers cytotoxic agent concentrations directly to tumor tissue while exhibiting a potent bystander effect on neighboring malignant cells. In pretreated populations who experience treatment failure on first-line regimens, overcoming secondary resistance mechanisms remains a critical clinical priority.
The safety profile remained consistent with the known pharmacologic mechanisms of topoisomerase-directed payloads. Treatment-related adverse events were predominantly hematologic and gastrointestinal, with cytopenias and nausea managed through routine supportive care and dose adjustments. Notably, the incidence of severe interstitial lung disease was minimal, presenting a favorable risk-benefit balance for continuous disease management.
For oncologists managing HER2-positive metastatic breast cancer, these Phase 3 results highlight an effective treatment approach that substantially prolongs remission. Incorporating next-generation antibody-drug conjugates into post-taxane regimens promises to redefine second-line paradigms and improve long-term outcomes for patients navigating advanced HER2-driven malignancy.
Reference
Yao H et al. Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2026;27(8):929-940.
Featured Image: Peakstock on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
